Targets › NTSR1
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Jul 2030.
G protein-coupled receptor for the tridecapeptide neurotensin (NTS). Signaling is effected via G proteins that activate a phosphatidylinositol-calcium second messenger system. (UniProt, P30989)
Open in Phaseline: the race on NTSR1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| SK Life Science | SKL35501 NTSR1-targeting small molecule linked to alpha emitter 225Ac | NTSR1 | Phase 1 | Selected Advanced Solid Tumors | Jul 2030 |
Selected Advanced Solid Tumors (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.